EcoDrugPlus

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSJJAG00000004398
Gene Symbol: PPARD
3 Cross references
418 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSJJAG00000023734
Gene Symbol: PPARG
3 Cross references
405 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSJJAG00000021453
Gene Symbol: PIK3CA
3 Cross references
275 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSJJAG00000023651
Gene Symbol: PIK3CB
3 Cross references
215 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSJJAG00000014634
Gene Symbol: PIK3CD
3 Cross references
213 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSJJAG00000010428
Gene Symbol: PDE10A
3 Cross references
205 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSJJAG00000013263
Gene Symbol: PDE3A
3 Cross references
272 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSJJAG00000003122
Gene Symbol: PDE3B
3 Cross references
217 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSJJAG00000022269
Gene Symbol: PDE4A
3 Cross references
275 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSJJAG00000015966
Gene Symbol: PDE4B
3 Cross references
295 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSJJAG00000017090
Gene Symbol: PDE4D
3 Cross references
244 Possible Orthologues:

Phosphodiesterase 5a

Ensembl ID : ENSJJAG00000018246
Gene Symbol: PDE5A
3 Cross references
220 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).